312 related articles for article (PubMed ID: 21569406)
41. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
[TBL] [Abstract][Full Text] [Related]
42. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH
Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347
[TBL] [Abstract][Full Text] [Related]
43. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E
J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338
[TBL] [Abstract][Full Text] [Related]
44. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries.
Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334
[TBL] [Abstract][Full Text] [Related]
45. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
[TBL] [Abstract][Full Text] [Related]
46. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
Moss JL; Reiter PL; Brewer NT
Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
[TBL] [Abstract][Full Text] [Related]
47. Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China.
Zhang Q; Liu YJ; Hu SY; Zhao FH
BMC Cancer; 2016 Nov; 16(1):848. PubMed ID: 27814703
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of HPV vaccination in Belize.
Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Kaló Z
BMC Public Health; 2012 Oct; 12():924. PubMed ID: 23110361
[TBL] [Abstract][Full Text] [Related]
50. Structural differences among cost-effectiveness models of human papillomavirus vaccines.
Insinga RP; Dasbach EJ; Elbasha EH
Expert Rev Vaccines; 2008 Sep; 7(7):895-913. PubMed ID: 18767941
[TBL] [Abstract][Full Text] [Related]
51. Impact and Cost-Effectiveness of Human Papillomavirus Vaccination Campaigns.
Portnoy A; Campos NG; Sy S; Burger EA; Cohen J; Regan C; Kim JJ
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):22-30. PubMed ID: 31666282
[TBL] [Abstract][Full Text] [Related]
52. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
Kim JJ; Goldie SJ
BMJ; 2009 Oct; 339():b3884. PubMed ID: 19815582
[TBL] [Abstract][Full Text] [Related]
53. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
54. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
55. Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia.
Setiawan D; Dolk FC; Suwantika AA; Westra TA; WIlschut JC; Postma MJ
Value Health Reg Issues; 2016 May; 9():84-92. PubMed ID: 27881267
[TBL] [Abstract][Full Text] [Related]
56. The health-economic studies of HPV vaccination in Southeast Asian countries: a systematic review.
Setiawan D; Oktora MP; Hutubessy R; Riewpaiboon A; Postma MJ
Expert Rev Vaccines; 2017 Sep; 16(9):933-943. PubMed ID: 28730914
[TBL] [Abstract][Full Text] [Related]
57. Human papilloma virus vaccine for low and middle income countries: A step too soon?
Jindal HA; Kaur A; Murugan S
Hum Vaccin Immunother; 2017 Nov; 13(11):2723-2725. PubMed ID: 28846491
[TBL] [Abstract][Full Text] [Related]
58. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
59. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.
Anonychuk AM; Bauch CT; Merid MF; Van Kriekinge G; Demarteau N
BMC Public Health; 2009 Oct; 9():401. PubMed ID: 19878578
[TBL] [Abstract][Full Text] [Related]
60. Cost effectiveness of human papilloma virus vaccination in low and middle income countries: a systematic review of literature.
Silas OA; Achenbach CJ; Murphy RL; Hou L; Sagay SA; Banwat E; Adoga AA; Musa J; French DD
Expert Rev Vaccines; 2018 Jan; 17(1):91-98. PubMed ID: 29183182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
